Yep, 1 month tomorrow (29th May) and - if still no approval - we would then be overtaking the two outliers Leqembi and Kisunla that followed the same National procedures pathway as DCVax-L. These very similar treatments for Alzheimer’s had highly complex safety red flags that involved the same restricted population approvals with mandatory genomic testing to correctly ID eligible patients and took 180 and 182 days respectively to go from their 2nd CHM meeting to MA.
I believe (and hope) that we will have news before then! 🤞
Market Data 
Markets 
AI
